 | • レポートコード：MRC2212B087 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、220ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：製薬 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査資料では、2021年に4,540.2億ドルであった世界の医薬品製造市場規模が、2022年に5,094.5億ドルに達し、2027年には9,149.0億ドルまで年平均12.38%で成長すると予測しています。当書は、医薬品製造の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、医薬品開発タイプ別（自社、他社）分析、剤形別（カプセル、注射剤、粉末、スプレー、その他）分析、治療領域別（癌、循環器系疾患、糖尿病、疼痛、呼吸器系疾患）分析、投与経路別（吸入、経口、非経口、外用）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめております。なお、当書には、Actiza Pharmaceutical Pvt. Ltd.、Aenova Group GmbH、AstraZeneca PLC、Bayer AG、Boehringer Ingelheim Group、Bristol-Myers Squibb、Catalent Inc.、Eli Lilly And Company、F. Hoffmann-La Roche Ltd.、Famar SA、GlaxoSmithKline PLCなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の医薬品製造市場規模：医薬品開発タイプ別 - 自社開発医薬品の市場規模 - 他社開発医薬品の市場規模 ・世界の医薬品製造市場規模：剤形別 - カプセルの市場規模 - 注射剤の市場規模 - 粉末の市場規模 - スプレーの市場規模 - その他剤形の市場規模 ・世界の医薬品製造市場規模：治療領域別 - 癌治療における市場規模 - 循環器系疾患治療における市場規模 - 糖尿病治療における市場規模 - 疼痛治療における市場規模 - 呼吸器系疾患治療における市場規模 ・世界の医薬品製造市場規模：投与経路別 - 吸入投与医薬品の市場規模 - 経口投与医薬品の市場規模 - 非経口投与医薬品の市場規模 - 外用投与医薬品の市場規模 ・世界の医薬品製造市場規模：地域別 - 南北アメリカの医薬品製造市場規模 アメリカの医薬品製造市場規模 カナダの医薬品製造市場規模 ブラジルの医薬品製造市場規模 ... - アジア太平洋の医薬品製造市場規模 日本の医薬品製造市場規模 中国の医薬品製造市場規模 インドの医薬品製造市場規模 韓国の医薬品製造市場規模 台湾の医薬品製造市場規模 ... - ヨーロッパ/中東/アフリカの医薬品製造市場規模 イギリスの医薬品製造市場規模 ドイツの医薬品製造市場規模 インドの医薬品製造市場規模 フランスの医薬品製造市場規模 ロシアの医薬品製造市場規模 ... - その他地域の医薬品製造市場規模 ・競争状況 ・企業情報 |
The Global Pharmaceutical Manufacturing Market size was estimated at USD 454.02 billion in 2021 and expected to reach USD 509.45 billion in 2022, and is projected to grow at a CAGR 12.38% to reach USD 914.90 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Pharmaceutical Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Development Type, the market was studied across In-house and Outsource.
Based on Formulation, the market was studied across Capsules, Injectable, Powders, Sprays, Suspensions, and Tablets.
Based on Therapy Area, the market was studied across Cancer, Cardiovascular Diseases, Diabetes, Pain, and Respiratory Diseases.
Based on Route of Administration Outlook, the market was studied across Inhalations, Oral, Parenteral, and Topical.
Based on Prescription, the market was studied across Over-the-counter (OTC) Medicines and Prescription Medicines.
Based on Age Group, the market was studied across Adults, Children & Adolescents, and Geriatric.
Based on Distribution Channels, the market was studied across Non-retail and Retail.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Pharmaceutical Manufacturing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pharmaceutical Manufacturing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pharmaceutical Manufacturing Market, including Actiza Pharmaceutical Pvt. Ltd., Aenova Group GmbH, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim Group, Bristol-Myers Squibb, Catalent Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Famar SA, GlaxoSmithKline PLC, Johnson & Johnson Private Limited, Lonza Group AG, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Piramal Pharma Solutions, Recipharm AB, Sanofi S.A., and Sun Pharmaceutical Industries Limited.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pharmaceutical Manufacturing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmaceutical Manufacturing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pharmaceutical Manufacturing Market?
4. What is the competitive strategic window for opportunities in the Global Pharmaceutical Manufacturing Market?
5. What are the technology trends and regulatory frameworks in the Global Pharmaceutical Manufacturing Market?
6. What is the market share of the leading vendors in the Global Pharmaceutical Manufacturing Market?
7. What modes and strategic moves are considered suitable for entering the Global Pharmaceutical Manufacturing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in global demand for vaccines and drugs
5.1.1.2. Growing pharmaceutical R&D spending
5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
5.1.2. Restraints
5.1.2.1. Patent expiration of profitable drugs
5.1.3. Opportunities
5.1.3.1. Rise in focus towards healthcare needs of emerging nations
5.1.3.2. Rise in the investment and funding programs in pharmaceutical manufacturing sector
5.1.3.3. Emergence in the advancements of pharmaceutical manufacturing technologies
5.1.4. Challenges
5.1.4.1. Logistics complexities and limited skilled professionals
5.2. Cumulative Impact of COVID-19
6. Pharmaceutical Manufacturing Market, by Drug Development Type
6.1. Introduction
6.2. In-house
6.3. Outsource
7. Pharmaceutical Manufacturing Market, by Formulation
7.1. Introduction
7.2. Capsules
7.3. Injectable
7.4. Powders
7.5. Sprays
7.6. Suspensions
7.7. Tablets
8. Pharmaceutical Manufacturing Market, by Therapy Area
8.1. Introduction
8.2. Cancer
8.3. Cardiovascular Diseases
8.4. Diabetes
8.5. Pain
8.6. Respiratory Diseases
9. Pharmaceutical Manufacturing Market, by Route of Administration Outlook
9.1. Introduction
9.2. Inhalations
9.3. Oral
9.4. Parenteral
9.5. Topical
10. Pharmaceutical Manufacturing Market, by Prescription
10.1. Introduction
10.2. Over-the-counter (OTC) Medicines
10.3. Prescription Medicines
11. Pharmaceutical Manufacturing Market, by Age Group
11.1. Introduction
11.2. Adults
11.3. Children & Adolescents
11.4. Geriatric
12. Pharmaceutical Manufacturing Market, by Distribution Channels
12.1. Introduction
12.2. Non-retail
12.3. Retail
13. Americas Pharmaceutical Manufacturing Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Pharmaceutical Manufacturing Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. Actiza Pharmaceutical Pvt. Ltd.
17.1.1. Business Overview
17.1.2. Key Executives
17.1.3. Product & Services
17.2. Aenova Group GmbH
17.2.1. Business Overview
17.2.2. Key Executives
17.2.3. Product & Services
17.3. AstraZeneca PLC
17.3.1. Business Overview
17.3.2. Key Executives
17.3.3. Product & Services
17.4. Bayer AG
17.4.1. Business Overview
17.4.2. Key Executives
17.4.3. Product & Services
17.5. Boehringer Ingelheim Group
17.5.1. Business Overview
17.5.2. Key Executives
17.5.3. Product & Services
17.6. Bristol-Myers Squibb
17.6.1. Business Overview
17.6.2. Key Executives
17.6.3. Product & Services
17.7. Catalent Inc.
17.7.1. Business Overview
17.7.2. Key Executives
17.7.3. Product & Services
17.8. Eli Lilly And Company
17.8.1. Business Overview
17.8.2. Key Executives
17.8.3. Product & Services
17.9. F. Hoffmann-La Roche Ltd.
17.9.1. Business Overview
17.9.2. Key Executives
17.9.3. Product & Services
17.10. Famar SA
17.10.1. Business Overview
17.10.2. Key Executives
17.10.3. Product & Services
17.11. GlaxoSmithKline PLC
17.11.1. Business Overview
17.11.2. Key Executives
17.11.3. Product & Services
17.12. Johnson & Johnson Private Limited
17.12.1. Business Overview
17.12.2. Key Executives
17.12.3. Product & Services
17.13. Lonza Group AG
17.13.1. Business Overview
17.13.2. Key Executives
17.13.3. Product & Services
17.14. Merck & Co., Inc.
17.14.1. Business Overview
17.14.2. Key Executives
17.14.3. Product & Services
17.15. Novartis AG
17.15.1. Business Overview
17.15.2. Key Executives
17.15.3. Product & Services
17.16. Pfizer, Inc.
17.16.1. Business Overview
17.16.2. Key Executives
17.16.3. Product & Services
17.17. Piramal Pharma Solutions
17.17.1. Business Overview
17.17.2. Key Executives
17.17.3. Product & Services
17.18. Recipharm AB
17.18.1. Business Overview
17.18.2. Key Executives
17.18.3. Product & Services
17.19. Sanofi S.A.
17.19.1. Business Overview
17.19.2. Key Executives
17.19.3. Product & Services
17.20. Sun Pharmaceutical Industries Limited
17.20.1. Business Overview
17.20.2. Key Executives
17.20.3. Product & Services
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing